Status:
COMPLETED
Effect of Continuous Intake of Ergothioneine-containing Supplements on Skin Condition
Lead Sponsor:
Shanghai EGT Synbio Group Co., Ltd.
Conditions:
Skin
Eligibility:
FEMALE
35-59 years
Phase:
NA
Brief Summary
This trial employed a non-randomized, double-blind, placebo-controlled design to evaluate the effects of DR. ERGO® Capsules (each containing 30mg of ergothioneine) on the skin condition of women aged ...
Detailed Description
Ergothioneine (EGT), a naturally occurring amino acid-like antioxidant, was first discovered in Clavieps purpurea in 1909. It is widely found in mushrooms, legumes, and certain animal tissues. Studies...
Eligibility Criteria
Inclusion
- ① Healthy women aged 35 to 59 years old.
- ② Individuals who feel that their skin condition is deteriorating (loss of radiance, dullness, pigmentation spots, etc.).
Exclusion
- Individuals with a history of food allergies.
- Pregnant or breastfeeding individuals.
- Individuals with inflammation or wounds on their face.
- Individuals taking medication that could affect the trial. ⑤ Individuals consuming health supplements that could affect the trial.
- ⑥ Individuals currently undergoing medical treatment or receiving prescriptions from a doctor.
- ⑦ Individuals undergoing hormone therapy.
- ⑧ Individuals with eyelash extensions, permanent eyeliner, or other forms of cosmetic tattooing around the eyes.
- ⑨ Individuals who have participated in human clinical trials within the last month or plan to do so during the trial period.
- ⑩ Individuals deemed unsuitable by the principal investigator of the trial.
Key Trial Info
Start Date :
October 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 3 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06886061
Start Date
October 9 2024
End Date
March 3 2025
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Japan Clinical Trial Association N.A.
Tokyo, Shinjukuku, Japan